Abstract 189P
Background
Malignant tumors are sophisticated, organized ecosystems in addition to collections of cancer cells. It has long been established that the formation, recurrence, and metastasis of cancers are all tightly correlated with their immune components. However, the impact of the tumor microenvironment in soft tissue sarcoma (STS) remains mainly unclear. Studying how the immunological microenvironment affects the clinical presentation and prognosis of soft tissue sarcomas is the objective.
Methods
Retrospective research was conducted on 168 soft tissue sarcoma patients who received care at the Republican specialized Scientific and practical Medical Center of Oncology and Radiology of Uzbekistan. Through immunohistochemistry analyses of CD3, CD4, CD8, CD20, and CD68, lymphocyte subpopulations that infiltrate tumours and their subpopulations were investigated.
Results
In the immunological microenvironment, CD 68+ macrophages and CD 3+ T cells were the most prevalent cell types. There was a substantial positive correlation between CD 68 expression and the probability of local recurrence (p = 0.014) in a multivariate analysis employing the Fine & Gray risk regression model with death as a competing event, independent of age, resection margins, and the presence of B cells. Furthermore, B cell abundance was significantly lower (p = 0.013) and macrophage abundance was much higher in patients older than middle age. Regarding histological subtypes, undifferentiated pleomorphic sarcoma and myxofibrosarcoma were more frequently found to have these cells, which had a high total number of tumor-infiltrating lymphocytes in general and macrophages in particular.
Conclusions
The significant number of CD 68 macrophages in soft tissue sarcomas and their detrimental effect on the prognosis for local recurrence are both confirmed by this investigation.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer
Presenter: Angelica Rigutto
Session: Poster Display
170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Presenter: Nicholas Venturini
Session: Poster Display
171P - Immune landscape and CLEVER-1 expression in hepatoblastoma
Presenter: Ville Väyrynen
Session: Poster Display
172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
Presenter: Ju Yang
Session: Poster Display
173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer
Presenter: Job Saris
Session: Poster Display
174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity
Presenter: Yizhi Zhan
Session: Poster Display
175P - MicroRNA-548c: An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer
Presenter: Alyaa Dawoud
Session: Poster Display
176P - Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Presenter: Andrea Joaquin Garcia
Session: Poster Display
177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Presenter: Bhawna Deswal
Session: Poster Display
178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.
Presenter: Charlotte Birchall
Session: Poster Display